Roche, Biogen Suffer Setback With Experimental Drug – Wall Street Journal
Posted under Business on Monday, March 8th, 2010 at 7:48 am | 
Comments are off for this article
 The Hindu |
Roche, Biogen Suffer Setback With Experimental Drug
Wall Street Journal ZURICH–Roche Holding AG and Biogen Idec Inc. said Monday they suspended a rheumatoid arthritis program using drug candidate ocrelizumab because of safety concerns, further cutting the experimental drug's market potential. … Roche suspends arthritis treatment after deaths Roche suspends arthritis drug study after deaths Roche And Biogen Idec (BIIB) Suspend Rheumatoid Arthritis Drug Program |
Read More: Roche, Biogen Suffer Setback With Experimental Drug – Wall Street Journal
